The Efficacy of Preseasonal Omalizumab Treatment

Inclusion Criteria: * Male or female outpatients aged 18 to 60 years (inclusive). * With history of SAR for at least two years, with/without conjunctivitis and without asthma * Two or more nasal symptoms scores were ≥ 2 points during July - October in the last year. * Sensitised to common autumn pollens including sagewort and ragweed (a specific IgE level ≥ 3.5 kU/L). * Patients who have been informed of the nature and aims of the study and have given their written consent, willing to comply with the protocol. * Patients who are able to understand the information given and the consent and complete the daily record card. Exclusion Criteria: * Patients with oral diseases/ allergies within the run-in period. * Patients accepted any kind of operations within 4 weeks of the run-in period. * Patients applied for systemic glucocorticoids within 4 weeks in the run-in period. * Patients with PAR. * Patients with any nasal condition that could confound the results of the study (chronic rhinitis, chronic rhinosinusitis with/without polyps). * Whatever the co-sensitization leading to clinically relevant AR, conjunctivitis or asthma likely to significantly change the symptoms of the patient throughout the study. * patients with comorbidity of severe asthma. * Patients applying beta-antagonist (local or systemic appliance). * Pregnant, breast-feeding / sexually active women of childbearing potential. * Patients treated with AIT for pollens within 3 years. * Participation in any clinical study within the 3 months of the run-in period. * Patients at risk of non-compliance.. * Patients with immunologic suppression, diabetes mellitus, autonomic neuropathy, coronary heart disease or hypertension.